[go: up one dir, main page]

HK1228393A1 - Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof - Google Patents

Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof Download PDF

Info

Publication number
HK1228393A1
HK1228393A1 HK17102000.5A HK17102000A HK1228393A1 HK 1228393 A1 HK1228393 A1 HK 1228393A1 HK 17102000 A HK17102000 A HK 17102000A HK 1228393 A1 HK1228393 A1 HK 1228393A1
Authority
HK
Hong Kong
Prior art keywords
f1fo
therapeutic uses
pyrazolyl guanidine
atpase inhibitors
trifluoromethyl pyrazolyl
Prior art date
Application number
HK17102000.5A
Other languages
Chinese (zh)
Inventor
Alexander R. Hurd
Clarke B. Taylor
Jian Wang
Peng Zhou
Original Assignee
莱斯拉公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 莱斯拉公司 filed Critical 莱斯拉公司
Publication of HK1228393A1 publication Critical patent/HK1228393A1/en

Links

Abstract

The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
HK17102000.5A 2013-12-10 2014-12-10 Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof HK1228393A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914085P 2013-12-10
US201461979619P 2014-04-15

Publications (1)

Publication Number Publication Date
HK1228393A1 true HK1228393A1 (en) 2017-11-03

Family

ID=

Similar Documents

Publication Publication Date Title
MX2016007445A (en) Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof.
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015073587A3 (en) Synthetic membrane-receiver complexes
HK1216175A1 (en) Therapeutic compounds and compositions
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
MX344590B (en) Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof.
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
WO2015001504A3 (en) Antibody formulations and methods
IL244182B (en) Compositions, methods and systems for the treatment of cutaneous disorders
PH12016501702B1 (en) Pyrazole amide derivative
MX2013006398A (en) Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof.
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
EA201690513A1 (en) COMBINATION OF MEK INHIBITOR AND ERK INHIBITOR FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
HK1219231A1 (en) Methods of treatment of pediatric solid tumor
HK1220155A1 (en) Methods for treating cancer
MD20160007A2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
MX2016014436A (en) Heterocyclyl-butanamide derivatives.
HK1220707A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX2016014559A (en) Compounds for treatment of cancer.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity